12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anti-IL-6R: Interim Phase II data

Interim data from 34 evaluable patients with moderate to severe active RA on a stable background of methotrexate in the Phase II portion of a double-blind, European Phase I/II trial showed that 3 mg/kg IV ALX-0061 every 4 weeks significantly improved ACR20 response rate at week 12 vs. placebo (80% vs. 17%, p<0.05). ALX-0061 non-significantly improved ACR20 response rates at week 12 vs. placebo when given in doses of 1 mg/kg every 4 weeks...

Read the full 356 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >